The Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference served as the stage for Conformal Medical, Inc. to present one-year data from its Early Feasibility Study (EFS) for the innovative CLAAS® Left Atrial Appendage Occlusion (LAAO) System. This advanced technology represents a transformative approach to reducing stroke risk in patients with non-valvular atrial fibrillation (Afib). Behind the scenes, Angio played a pivotal role in ensuring the success of these milestone presentations and live procedures by procuring the essential medical devices and accessories that enabled seamless clinical execution.
The Promise of the CLAAS® System
Atrial fibrillation (Afib) patients at increased risk of stroke often face limited treatment options, with anticoagulants being the standard but challenging solution. The CLAAS System offers a groundbreaking alternative by sealing the left atrial appendage (LAA) using a proprietary foam-based implant. This approach eliminates the need for anticoagulants while accommodating a wide range of LAA anatomies with just two device sizes, streamlining both the implantation procedure and patient care.
The Early Feasibility Study (EFS) demonstrated the safety and performance of the CLAAS System over one year, with results presented by Dr. William Gray at TCT 2023. These findings, coupled with live demonstrations of the system’s capabilities, highlighted the device’s potential to revolutionize stroke prevention in Afib patients.
Advancing Innovation in Cardiac Care
Conformal Medical’s CLAAS System represents a leap forward in LAAO technology, offering hope to millions of Afib patients worldwide. The success of their TCT 2023 presence underscores the importance of partnerships that enable innovation. Angio’s role extended beyond procurement—it was about empowering Conformal Medical to deliver on their vision of safer, more efficient stroke prevention.
A Commitment to Transforming Healthcare
We, we take pride in supporting medical innovators like Conformal Medical. By providing end-to-end solutions that simplify complex challenges, we help bring groundbreaking technologies to life, improving outcomes for patients and clinicians alike.
As Conformal Medical continues its pivotal CONFORM trial to achieve U.S. commercialization, Angio remains a trusted partner, ready to support the journey ahead. Together, we’re shaping the future of cardiovascular care—one milestone at a time.
Contact Angio to learn more about how we can support your next medical innovation.
